The non-profit organization, Hereditary Neuropathy Foundation (HNF), focuses on increasing awareness, accurate diagnosis, and improving the quality of life for patients with Charcot-Marie-Tooth (CMT) and related inherited neuropathies. HNF collaborates with academia, government, and industry through its Therapeutic Research in Accelerated Discovery (TRIAD) program to develop treatments for CMT. Currently, clinical trials are underway for the most common type of CMT, CMT1A, and other drugs and gene therapies are being developed for other types of CMT. For more information, visit https://www.hnf-cure.org/charcot-marie-tooth-research/.